title: Tumour lysis syndrome in haematological malignancies.
abstract: The tumour lysis syndrome, a combination of metabolic derangements, is a complication of intensive cytotoxic chemotherapy, especially in rapidly proliferating lymphoid malignancies. During the last three years we have encountered four cases with different forms of haematological neoplasms, all of whom developed tumour lysis, i.e. some degree of hyperuricaemia, hyperkalaemia, hyperphosphataemia or hypocalcaemia, resulting in renal, circulatory and/or respiratory failure. Relevant literature is reviewed.
authors.affiliation: Department of Haematology, Daniël den Hoed Cancer Centre, Rotterdam, Netherlands.
authors.forename: B
authors.initials: B
authors.lastname: van der Hoven
authors.forename: P L
authors.initials: PL
authors.lastname: Thunnissen
authors.forename: W
authors.initials: W
authors.lastname: Sizoo
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000378:metabolism / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents